WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 04/07/2024 am IST			5-day change	1st Jan Change
37.6 ^CNY	-2.84%		-6.49%	-48.32%

12/06	WuXi AppTec Co., Ltd. Approves Cash Dividend Payment for the Financial Year Ended 31 December 2023, Payable on July 5, 2024	CI
06/06	Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	RE

Tranche Update on WuXi AppTec Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.

May 23, 2024 at 09:30 pm IST

From April 1, 2024 to May 22, 2024, the company has repurchased 15,074,554 shares, representing 0.52% for CNY 668.89 million. With this, the company has completed the repurchase of 21,593,780 shares, representing 0.74% for CNY 1,000 million under the buyback announced on March 8, 2024.

Latest news about WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd. Approves Cash Dividend Payment for the Financial Year Ended 31 December 2023, Payable on July 5, 2024	12/06	CI
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists	06/06	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06	RE
Wuxi Apptec Breaks Ground on Singapore R&D Site	24/05	MT
Wuxi Apptec Completes Repurchase of Nearly 22 Million Shares with 1 Billion Yuan	24/05	MT
Tranche Update on WuXi AppTec Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	23/05	CI
WuXi AppTec Co., Ltd.'s Equity Buyback announced on March 8, 2024, has closed with 21,593,780 shares, representing 0.74% for CNY 1,000 million.	22/05	CI
WuXi AppTec Denies Being a Security Threat to US	16/05	MT
HONG KONG SHARES OF WUXI APPTEC SET TO OPEN DOWN 2.1% AFTER US H…	16/05	RE
US House committee advances bill to restrict BGI, WuXi AppTec	15/05	RE
US HOUSE OVERSIGHT COMMITTEE VOTES TO ADVANCE LEGISLATION RESTRI…	15/05	RE
US House committee to vote on bill to restrict BGI, WuXi AppTec	15/05	RE
Chinese Stocks Muted as Investors Eye US Inflation Data, New Tariffs; Wuxi AppTec Rises Despite Biosecure Act Draft	14/05	MT
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms	14/05	MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	13/05	DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties	10/05	RE
Wuxi Apptec Co., Ltd. Proposes Final Cash Dividend Payment for the Financial Year Ended 31 December 2023	09/05	CI
Trade association survey shows 79% of US biotech companies contract with Chinese firms	09/05	RE
Beijing, Fed Churn Asian Stock Markets in Sparse Trading	03/05	MT
WuXi AppTec Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2024	29/04	CI
Interest Rate Outlooks Quell Asian Stock Markets	17/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	12/04	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04	MT

Chart WuXi AppTec Co., Ltd.

Duration

Period

More charts

Company Profile

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Sector

Biotechnology & Medical Research

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi AppTec Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38.7 CNY

Average target price

68.33 CNY

Spread / Average Target

+76.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI APPTEC CO., LTD.	-48.32%	14.89B
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+17.82%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.58%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B
INSMED INCORPORATED	+100.06%	10B

Bio Therapeutic Drugs